2026 Global Biotech & Pharma Patent (China) Summit 中國主要醫(yī)藥企業(yè)專 利活動概況
RankCompany (English)Company (Chinese)Patent Portfolio Profile & Key Focus Areas1Jiangsu Hengrui Pharmaceuticals Co., Ltd.江蘇恒瑞醫(yī)藥股份有限公司W(wǎng)idely recognized as the most innovative traditional pharma in China. Holds a massive and high-quality patent portfolio, leading in small molecule drugs, oncology, and autoimmune diseases.2Zhejiang Hisun Pharmaceutical Co., Ltd.浙江海正藥業(yè)股份有限公司A leader in generic APIs and innovative biologics. Maintains a very high volume of patent filings, particularly strong in fermentation processes and biosimilars.3BeiGene, Ltd.百濟(jì)神州有限公司A global biotech leader. Its patent strategy is deeply integrated with R&D, focusing on oncology (especially BTK inhibitors). Numerous international PCT applications.4Innovent Biologics, Inc.信達(dá)生物制藥(蘇州)有限公司A top biologics innovator. Extensive patent portfolio covering antibodies, cancer immunotherapy (e.g., PD-1), and protein engineering.5Jiangsu Hansoh Pharmaceutical Group Co., Ltd.江蘇豪森藥業(yè)集團(tuán)有限公司Strong in CNS diseases and oncology. Has a substantial and growing patent portfolio, focusing on new drug forms and combination therapies.6Shanghai Junshi Biosciences Co., Ltd.上海君實生物醫(yī)藥科技股份有限公司Key player in immune-oncology. Core patents revolve around its anti-PD-1 antibody (toripalimab) and next-generation immuno-therapies.7CSPC Pharmaceutical Group Limited石藥集團(tuán)有限公司A diversified giant with significant patent output in both small molecules and biologics, including antibody-drug conjugates (ADCs).8Luye Pharma Group Ltd.綠葉制藥集團(tuán)有限公司Strong focus on novel drug delivery systems (e.g., microspheres, liposomes). Its patent portfolio is specialized in formulation technology and sustained-release mechanisms.9Zhuhai Hokai Medical Instruments Co., Ltd. (as a representative of high-patent MedTech)珠海和佳醫(yī)療設(shè)備股份有限公司 (醫(yī)療器械代表)To highlight the medical device sector, which is also patent-intensive. Companies like Hokai hold numerous patents in interventional radiology and tumor therapy devices.10Wuxi Biologics (Cayman) Inc.無錫藥明生物技術(shù)有限公司The world's leading CRDMO. Its vast patent portfolio is unique, focusing on platform technologies, cell line development, and biomanufacturing processes rather than end products. https://en.zenseegroup.com/p/1176775/ 2026 Global Biotech & Pharma Patent (China) Summit